ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Tempest Therpeutics Inc

Tempest Therpeutics Inc (TPST)

1.35
-0.06
(-4.26%)
Closed September 20 4:00PM
1.3501
0.0001
(0.01%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.3501
Bid
1.35
Ask
1.40
Volume
415,256
1.35 Day's Range 1.44
0.17 52 Week Range 9.77
Market Cap
Previous Close
1.41
Open
1.44
Last Trade Time
Financial Volume
$ 576,025
VWAP
1.3872
Average Volume (3m)
2,547,262
Shares Outstanding
25,207,792
Dividend Yield
-
PE Ratio
-1.15
Earnings Per Share (EPS)
-1.17
Revenue
-
Net Profit
-29.49M

About Tempest Therpeutics Inc

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Tempest Therpeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TPST. The last closing price for Tempest Therpeutics was $1.41. Over the last year, Tempest Therpeutics shares have traded in a share price range of $ 0.17 to $ 9.77.

Tempest Therpeutics currently has 25,207,792 shares outstanding. The market capitalization of Tempest Therpeutics is $35.54 million. Tempest Therpeutics has a price to earnings ratio (PE ratio) of -1.15.

TPST Latest News

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall survival, the strongest result from the Phase 2 trial, will be the primary study...

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Β Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (β€œHCC”) study demonstrating: Survival benefit maintained across key...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.02011.511278195491.331.541.334611541.44605848CS
4-0.1399-9.389261744971.491.541.120054475141.3589112CS
12-0.8299-38.06880733942.182.310.924125472621.52675339CS
26-2.3899-63.90106951873.7460.924118501202.19650025CS
520.8626176.9435897440.48759.770.1738623465.08299044CS
156-13.2499-90.75273972614.615.66690.1713589134.95630262CS
260-12.4599-90.223750905113.81410.1713132875.53762163CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BNZIBanzai International Inc
$ 5.645
(96.01%)
61.39M
ZJYLJin Medical International Ltd
$ 3.975
(50.00%)
1.24M
ANEBAnebulo Pharmaceuticals Inc
$ 2.9001
(39.43%)
78.85k
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
AENTAlliance Entertainment Holding Corporation
$ 2.74
(34.31%)
4.23M
GSIWGarden Stage Ltd
$ 1.34
(-82.89%)
26.41M
CRBPCorbus Pharmaceuticals Holdings Inc
$ 19.51
(-62.26%)
12.29M
LGCBLinkage Global Inc
$ 0.4183
(-57.70%)
2.16M
BFIBurgerFi International Inc
$ 0.0855
(-42.27%)
15.04M
SKYESkye Bioscience Inc
$ 3.17
(-42.26%)
5.14M
XPONExpion360 Inc
$ 0.081
(39.18%)
1.46B
NVDANVIDIA Corporation
$ 116.00
(-1.59%)
377.83M
AAPLApple Inc
$ 228.20
(-0.29%)
320.78M
INTCIntel Corporation
$ 21.84
(3.31%)
261.64M
VERBVerb Technology Company Inc
$ 0.0742
(33.45%)
178.64M

TPST Discussion

View Posts
georgie18 georgie18 3 days ago
TPST...$1.50s clearing into the close...🥳
πŸ‘οΈ0
georgie18 georgie18 1 week ago
Have a Great Weekend Y'all...🥳
πŸ‘οΈ0
georgie18 georgie18 1 week ago
Nice...will be very pleased with 1/2 that target...🥳
πŸ‘οΈ0
glens0 glens0 1 week ago
Bought a starter today.
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
12:54 PM ET 8/15/24 | Dow Jones
πŸ‘οΈ0
georgie18 georgie18 1 week ago
TPST...$1.35...🥳
πŸ‘οΈ0
georgie18 georgie18 3 weeks ago
TPST...$1.44...HOD...🥳
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
TPST...$1.50...Off the .90 range dip...🥳...was $6 recently...setting up for a Breakout...imo...we shall see...
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...1.4995...HOD...Beauty move off the .90 range dip...🥳Was $6 a couple of months ago...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.60 off the $2 plus move from .90 range...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$2.00 ...Clearing here...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.24...🥳...BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).

"We are thrilled with the positive outcome of our end-of-Phase 2 meeting with the FDA,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest. β€œTempest and the FDA are in broad agreement on all major aspects of the proposed pivotal Phase 3 clinical trial for amezalpat in patients with hepatocellular carcinoma in the first line setting. This planned Phase 3 study closely mirrors the randomized Phase 2 study and the strongly favorable hazard ratio for overall survival observed at top-line analysis of the Phase 2, confirmed at the latest survival follow-up, give us confidence in the potential success of the Phase 3.”

Key outcomes of the FDA meeting include:

Agreement on Phase 3 study design, including the standard-of-care control arm and the primary and secondary study endpoints
Agreement on appropriateness of the current amezalpat dose and schedule for the Phase 3 study
Agreement on the Phase 3 statistical plan including a pre-specified early efficacy analysis that the company currently estimates could shorten the time to primary analysis by up to 8 months
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.25s clearing here...off the .90 range dip...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.17s clearing here...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.20...added more in this range...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.21s clearing here as volume hits...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.05...Setting up Bullish Harami...Reversal Pattern...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...97...added a few here...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.16...Taking a hit on earnings...adding more down here...🥳
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.53s clearing here...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
TPST...$1.80...setting up Reversal Candle here...adding...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
Yup...nice buy for the CEO...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
TPST...$2.14...adding down here...🥳
πŸ‘οΈ0
Hitman970 Hitman970 2 months ago
Form 4
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$2.25s clearing here...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$2.18...Forming a Bullish Engulfing Candle...🥳
πŸ‘οΈ0
peterus peterus 3 months ago
fucking turds
πŸ‘οΈ0
Roadtojourney Roadtojourney 3 months ago
Lol offering upsized right after the news..
πŸ‘οΈ0
tw0122 tw0122 3 months ago
in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m.
πŸ‘οΈ0
rouge Vaughn rouge Vaughn 6 months ago
yup and time to go up even more let's pass 7 and up trmw
πŸ‘οΈ0
TheFinalCD TheFinalCD 6 months ago
UPstink today
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
TPST under $4
πŸ‘οΈ0
retireat40 retireat40 9 months ago
El stinko day today
πŸ‘οΈ0
BurgerKing82 BurgerKing82 9 months ago
Any other bio cheapies besides hook
πŸ‘οΈ0
Triple nickle Triple nickle 9 months ago
Was that you 3.12 big
πŸ‘οΈ0
ORCA ORCA 9 months ago
OUT AT 3.53:))))
πŸ‘οΈ0
ORCA ORCA 9 months ago
$3.43:))))
πŸ‘οΈ0
ORCA ORCA 9 months ago
FROM 2.92 MY CALL.NOW 3.38:))))
πŸ‘οΈ0
ORCA ORCA 9 months ago
AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.
πŸ‘οΈ0
ORCA ORCA 9 months ago
ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))
πŸ‘οΈ0
MightyX MightyX 9 months ago
This is their reload zone evidently..price going higher
πŸ‘οΈ0
MightyX MightyX 10 months ago
Under 15min remaining for them to fake-volume trade this..lol
πŸ‘οΈ0
MightyX MightyX 10 months ago
Price rising with volume
πŸ‘οΈ0
MightyX MightyX 10 months ago
Wonder which partner Tempest selects for its TPST treatment.
πŸ‘οΈ0
MightyX MightyX 10 months ago
β€œTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”
πŸ‘οΈ0
MightyX MightyX 10 months ago
20k share trade at $3.42
πŸ‘οΈ0
MightyX MightyX 10 months ago
Grabbed $3.50’s..should find out who they partnered with..soon enough
πŸ‘οΈ0
MightyX MightyX 10 months ago
Grabbed some $3.70’s for next run over $5
πŸ‘οΈ0
MightyX MightyX 10 months ago
Must be todays conference causing rally
πŸ‘οΈ0
MightyX MightyX 10 months ago
Up 13%
πŸ‘οΈ0
MightyX MightyX 10 months ago
Up 12% 2nd million..let’s see 3rd
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock